These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 2973413)

  • 1. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies.
    Bindon CI; Hale G; Waldmann H
    Eur J Immunol; 1988 Oct; 18(10):1507-14. PubMed ID: 2973413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement activation by immunoglobulin does not depend solely on C1q binding.
    Bindon CI; Hale G; Waldmann H
    Eur J Immunol; 1990 Feb; 20(2):277-81. PubMed ID: 2311645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanism of synergistic complement-mediated lysis of rat red cells by monoclonal IgG antibodies.
    Hughes-Jones NC; Gorick BD; Howard JC
    Eur J Immunol; 1983 Aug; 13(8):635-41. PubMed ID: 6603980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the first component of complement, C1, by a monoclonal antibody recognizing the C chain of C1q.
    Heinz HP; Burger R; Golan MD; Loos M
    J Immunol; 1984 Feb; 132(2):804-8. PubMed ID: 6606678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the first component of human complement, C1, by monoclonal antibodies directed against different domains of subcomponent C1q.
    Kilchherr E; Schumaker VN; Phillips ML; Curtiss LK
    J Immunol; 1986 Jul; 137(1):255-62. PubMed ID: 3486914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of C1q by monoclonal antibodies.
    Heinz HP; Loos M
    Behring Inst Mitt; 1984 Nov; (76):42-58. PubMed ID: 6335397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal anti-mouse macrophage antibodies recognize the globular portions of C1q, a subcomponent of the first component of complement.
    Heinz HP; Dlugonska H; Rüde E; Loos M
    J Immunol; 1984 Jul; 133(1):400-4. PubMed ID: 6609989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD45 molecule cross-linking inhibits natural killer cell-mediated lysis independently of lytic triggering.
    Starling GC; Hart DN
    Immunology; 1990 Oct; 71(2):190-5. PubMed ID: 2146214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic complement lysis by monoclonal antibodies to the human leukocyte common antigen requires both the classical and alternative pathways.
    Bindon CI; Hale G; Hughes-Jones N; Gorick B; Waldmann H
    Mol Immunol; 1987 Jun; 24(6):587-94. PubMed ID: 2958690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bi-specific monoclonal antibodies: selective binding and complement fixation to cells that express two different surface antigens.
    Wong JT; Colvin RB
    J Immunol; 1987 Aug; 139(4):1369-74. PubMed ID: 3112233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of C1 activation by a monoclonal anti-C1q antibody and its (Fab)2 fragments.
    Kilchherr E; Schumaker VN; Bianchino AC; Curtiss LK
    J Immunol; 1987 Feb; 138(3):849-55. PubMed ID: 3492535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody density on rat red cells determines the rate of activation of the complement component C1.
    Hughes-Jones NC; Gorick BD; Howard JC; Feinstein A
    Eur J Immunol; 1985 Oct; 15(10):976-80. PubMed ID: 2996908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The binding site for C1q on IgG.
    Duncan AR; Winter G
    Nature; 1988 Apr; 332(6166):738-40. PubMed ID: 3258649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo immunosuppression by pan-T cell antibodies relates to their isotype and to their C1q uptake.
    Kummer U; Thierfelder S; Hoffmann-Fezer G; Schuh R
    J Immunol; 1987 Jun; 138(12):4069-74. PubMed ID: 2884259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodies.
    Lohse S; Peipp M; Beyer T; Valerius T; Dechant M
    Arch Immunol Ther Exp (Warsz); 2010 Aug; 58(4):303-12. PubMed ID: 20508996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of effector functions by immune complexes of mouse IgG2a with isotype-specific autoantibodies.
    Rajnavölgyi E; Fazekas G; Lund J; Daeron M; Teillaud JL; Jefferis R; Fridman WH; Gergely J
    Immunology; 1995 Apr; 84(4):645-52. PubMed ID: 7540592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
    de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
    Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antilymphocytic antibodies and marrow transplantation. XIV. Antibody-induced suppression of graft-versus-host disease in C3-decomplemented mice differentiates two T-cell-depletion pathways.
    Thierfelder S; Mysliwietz J; Hoffmann-Fezer G; Kummer U
    Blood; 1991 May; 77(10):2285-91. PubMed ID: 2029584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies reactive with class II antigens encoded for by the major histocompatibility complex inhibit human B cell activation.
    Clement LT; Tedder TF; Gartland GL
    J Immunol; 1986 Apr; 136(7):2375-81. PubMed ID: 3485149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
    Imai M; Ohta R; Varela JC; Song H; Tomlinson S
    Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.